While most approved antibody therapies – like Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) – are based ...

The properties of the different IgG isotypes should ... for the original or a different half-molecule and is driven by the relative amounts of both parent antibodies. An excess of either antibody ...

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer antibody company.” Both companies are focused on immunoglobulin antibodies, with ...

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...

This phenomenon leads to the production of an excessive amount of another antibody, immunoglobulin G (IgG). Under normal conditions, "vaccines generate a response through pneumococcus-specific IgG ...

The combined company will clinically advance Epsilogen's MOv18 IgE antibody in ovarian cancer and TigaTx's anti-EGFR IgA antibody.

Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces that it has completed the acquisition of TigaTx, Inc., a biotechnology company ...